Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis

OBJECTIVE: To evaluate long-term clinical, functional and radiographic outcomes in an open-label extension (OLE) study in patients with rheumatoid arthritis (RA) receiving adalimumab monotherapy or adalimumab+methotrexate following attainment of low disease activity (LDA) with adalimumab+methotrexat...

Descripción completa

Detalles Bibliográficos
Autores principales: Keystone, Edward C, Breedveld, Ferdinand C, Kupper, Hartmut, Li, Yihan, Florentinus, Stefan, Sainsbury, Iain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018859/
https://www.ncbi.nlm.nih.gov/pubmed/29955381
http://dx.doi.org/10.1136/rmdopen-2017-000637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018859/
https://www.ncbi.nlm.nih.gov/pubmed/29955381
http://dx.doi.org/10.1136/rmdopen-2017-000637

Ejemplares similares